Zevra Therapeutics (ZVRA) Total Liabilities (2014 - 2026)

Zevra Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $72.8 million for Q1 2026.

• Quarterly Total Liabilities fell 44.74% year-over-year to $72.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.8 million (down 44.74% YoY) and the FY2025 annual result came in at $130.1 million, down 6.06% from the prior year.
• Total Liabilities was $72.8 million for Q1 2026 at Zevra Therapeutics, down from $130.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $139.0 million in Q2 2025 and bottomed at $4.2 million in Q1 2022.
• A 5-year average of $84.5 million and a median of $102.5 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities plunged 72.99% — and 2024, when it soared 1063.03%.
• Zevra Therapeutics' Total Liabilities stood at $40.2 million in 2022, then surged by 174.65% to $110.5 million in 2023, then increased by 25.35% to $138.5 million in 2024, then declined by 6.06% to $130.1 million in 2025, then slumped by 44.05% to $72.8 million in 2026.
• Business Quant data shows ZVRA's Total Liabilities at $72.8 million in Q1 2026, $130.1 million in Q4 2025, and $137.0 million in Q3 2025.